Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jan:96:1-13.
doi: 10.1016/j.jaut.2018.11.001. Epub 2018 Nov 16.

Systemic lupus erythematosus: Diagnosis and clinical management

Andrea Fava  1 , Michelle Petri  2
Affiliations
Review

Systemic lupus erythematosus: Diagnosis and clinical management

Andrea Fava et al. J Autoimmun. 2019 Jan.

Abstract

Systemic lupus erythematosus (SLE) is a worldwide chronic autoimmune disease which may affect every organ and tissue. Genetic predisposition, environmental triggers, and the hormonal milieu, interplay in disease development and activity. Clinical manifestations and the pattern of organ involvement are widely heterogenous, reflecting the complex mosaic of disrupted molecular pathways converging into the SLE clinical phenotype. The SLE complex pathogenesis involves multiple cellular components of the innate and immune systems, presence of autoantibodies and immunocomplexes, engagement of the complement system, dysregulation of several cytokines including type I interferons, and disruption of the clearance of nucleic acids after cell death. Use of immunomodulators and immunosuppression has altered the natural course of SLE. In addition, morbidity and mortality in SLE not only derive from direct immune mediated tissue damage but also from SLE and treatment associated complications such as accelerated coronary artery disease and increased infection risk. Here, we review the diagnostic approach as well as the etiopathogenetic rationale and clinical evidence for the management of SLE. This includes 1) lifestyle changes such as avoidance of ultraviolet light; 2) prevention of comorbidities including coronary artery disease, osteoporosis, infections, and drug toxicities; 3) use of immunomodulators (i.e. hydroxychloroquine and vitamin D); and 4) immunosuppressants and targeted therapy. We also review new upcoming agents and regimens currently under study.

Keywords: Diagnosis; Management; Systemic lupus erythematosus.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Petri M, Epidemiology of systemic lupus erythematosus, Best Pract. Res. Clin. Rheumatol 16 (2002) 847–858. doi:10.1053/berh.2002.0259. - DOI - PubMed
    1. Johnson AE, Gordon C, Palmer RG, Bacon PA, The prevalence and incidence of systemic lupus erythematosus in Birmingham, England: Relationship to ethnicity and country of birth, Arthritis Rheum. 38 (1995) 551–558. doi:10.1002/art.1780380415. - DOI - PubMed
    1. Danchenko N, Satia J, Anthony M, Epidemiology of systematic lupus erythematosus: a comparison of worldwide disease burden, Lupus. 12 (2006) 308–318. http://lup.sagepub.com.proxygw.wrlc.org/content/15/5/308.full.pdf+html. - PubMed
    1. Symmons DPM, Occasional Series: Lupus Around the World Frequency of lupus in people of African origin, Lupus. 4 (1995) 176–178. doi:10.1177/096120339500400303. - DOI - PubMed
    1. Pons-Estel GJ, Alarcón GS, Scofield L, Reinlib L, Cooper GS, Understanding the Epidemiology and Progression of Systemic Lupus Erythematosus, Semin. Arthritis Rheum 39 (2010) 257–268. doi:10.1016/j.semarthrit.2008.10.007. - DOI - PMC - PubMed

Publication types

MeSH terms